Dr. Murray serves as a Gastroenterologist in the Division of Gastroenterology and Hepatology at the Mayo Clinic in Rochester, Minnesota. He founded a celiac disease clinic at the University of Iowa in 1992. In 1998, Dr. Murray joined the staff of Mayo clinic, where he runs the celiac disease research and clinical program that focuses on epidemiology, complications and mouse models of gluten sensitivity. In addition, Dr. Murray is a Professor of Medicine at the Mayo clinic in Rochester, Minnesota. He serves as a Consultant to several companies and has broad experience with clinical trials. Dr. Murray is an Associate Editor of Clinical Gastroenterology and Hepatology as well as an expert reviewer for many scientific journals. He has published over 100 scientific articles and has several patents on novel devices for the treatment of GI disorders. He has a large clinical practice widely focused on celiac disease and has been elected to the Best doctors in America from 2001 to 2006. He received his medical training in Ireland and GI training from the University of Iowa.
Dr. Kelly is a Professor of Medicine, Harvard Medical School, Chief of the Herrman L. Blumgart Internal Medicine Firm, Dir. of Gastroenterology Training and Medical Director of the Celiac Center at BIDMC He also heads clinical, research and educational programs in celiac disease as Medical Director of the Celiac Center at BIDMC. Dr. Kelly is the author of more than 150 clinical and basic research peer-reviewed publications. Dr. Kelly earned his doctor of medicine degree from Trinity College in Dublin, Ireland where he was a Foundation Scholar and recipient of numerous academic awards. Dr. Kelly has also received postgraduate clinical and research awards from the Crohn's and Colitis Foundation of America, the American Gastroenterological Association and the National Institutes of Health.
Dr. DiMarino is the William Rorer Professor of Medicine, Chief of the Division of Gastroenterology and Hepatology at Thomas Jefferson University Hospital, Director, Celiac Center. Dr. DiMarino is also founder of the first Adult Celiac Center in Philadelphia. Dr. DiMarino’s research interests have primarily been in the areas of esophageal, small intestinal motility, celiac disease and the safety of gastrointestinal endoscopy. Dr. DiMarino is the author of more than 300 original papers. He received his medical degree from Hahnemann Medical College and completed his internal medicine residency and fellowship in gastroenterology and served on the full-time faculty at the Hospital of the University of Pennsylvania.
Dr. Green is the Director of The celiac disease Center at Columbia University. He is a Professor of Clinical Medicine at the College of Physicians and Surgeons, Columbia University and Attending Physician at the New York-Presbyterian Hospital. Dr. Green received his medical degree from University of Sydney, Australia. After completing his Residency and GI fellowship in Sydney he became a Research fellow at Harvard Medical School and in the Gastroenterology Department at the Beth Israel Hospital in Boston. He is a Fellow of the Royal Australasian College of Physicians and the American College of Gastroenterology as well as a Member of the American Gastroenterologic Association and American Society of Gastrointestinal Endoscopy.
Celiac disease has been Dr. Green’s focus over the last 10 years with equal concentration on patient care and research. He is one of the few physicians in the United States with an intense clinical and academic interest and expertise in celiac disease. As a result of the need for a coordinated approach for the medical care of patients with celiac disease Dr. Green established the celiac disease Center at Columbia University. He is the author of the book celiac disease: A Hidden Epidemic. Dr. Green’s initial research involved studies of absorption of fats in the small intestine and the contribution of intestinal lipids to the lipids in the systemic circulation. His main clinical and research pursuits, over the last 12 years, have been in the clinical care and investigation of patients with celiac disease. As a result of his interest in this disease Dr. Green has cared for more than 500 patients with this condition. He has developed research programs with colleagues at Columbia University and other institutions into the epidemiology, genetics, diagnosis and management of celiac disease and its complications. In addition, he has lectured on celiac disease at many medical institutions throughout the United States as well as national and international meetings.
Dr. Mäki is professor (emeritus) at the University of Tampere and presently research director at the Tampere University Hospital, Tampere, Finland. He has an extensive track record in celiac disease research. Prof. Mäki’s research has been inspired by the needs of the celiac sufferers and he has been an active participant and advocate in the nationwide patient organization, also been the President of the Finnish Celiac Society. Lately professor Mäki has been involved in novel drug trials in celiac disease and his interest is especially in outcome measures. He is also a member of the Advisory Board in several companies focusing on celiac disease. Moreover, he has organized several international scientific celiac disease symposia. In 2010, Professor Mäki received the Wm. K. Warren Jr. Prize in celiac disease in Clinical/Translational Research, San Diego, USA. Mäki is a permanent member of the Finnish Academy of Science and Letters and the President of Finland has granted him the honor of Knight, First Class, of the Order of the White Rose of Finland in 2006.
Dr. Verdú is Associate Professor, Department of Medicine. Dr. Verdú became a faculty member at McMaster University in 2006, and her research focuses on the pathophysiology of inflammatory disorders such as IBD and celiac disease, with emphasis on diet-microbiota interactions. Dr. Verdú is the director of the Axenic Gnotobiotic Unit at McMaster University and holds a Canada Research Chair in Intestinal Inflammation, Microbiota, and Nutrition. She has received several research awards including the Canadian Celiac Association’s J.A. Campbell Research Award, Master’s in Gastroenterology by the American Gastroenterology Association and Young Investigator Award and Visiting Research Professor by the Canadian Gastroenterology Association. She is President of the North American Society for the Study of Celiac Disease. Dr. Verdú studied medicine at the University of Buenos Aires and completed a residency in Internal Medicine in Buenos Aires. During her residency, she lectured on Human Physiology at the University of Buenos Aires. She then obtained a fellowship from the Swiss National Foundation, moved to Lausanne, Switzerland, to work with Professor Andre Blum in clinical research. There, she studied the interaction between chronic infection with Helicobacter pylori and proton pump inhibitors on gastric acid secretion, bacterial overgrowth, and chronic gastritis in humans. During her Doctoral work in the Department of Gnotobiology and Microbiology at the Czech Academy of Science (working with Professor Helena Tlaskalova), she gained experience in animal models of inflammatory bowel disease (the most common and chronic inflammatory condition of the human bowel), intestinal microbiota, and gnotobiotic work. As a post-doctoral fellow at McMaster University, she worked on the role of probiotics in animal models of gut functional diseases.
Dr. Diehl is a Phi Beta Kappa, cum laude graduate of Georgetown University (1974), was elected to Alpha Omega Alpha as a junior medical student, and awarded the Janet M. Glasgow Award for women who graduate first in their medical school class, as well as the Kober medal for overall academic excellence, when she graduated summa cum laude from Georgetown University School of Medicine (1978). Dr. Diehl completed her internship and residency in internal medicine (1978-81), as well as her fellowship in gastroenterology at Johns Hopkins University (1981-84).
After serving at the Uniformed Services University for the Health Services in the US Army, she joined the faculty of the Division of Gastroenterology and Hepatology at Johns Hopkins as an Assistant Professor in 1987 and was promoted to full Professor in 1997. In 2004, the Hopkins Task Force on Women’s Academic Careers honored her for leadership in academic medicine. Dr. Diehl was recruited to Duke to direct its Gastroenterology and Hepatology programs in 2004.
During her 10 years as chief, Gastroenterology doubled both its research portfolio and number of clinical faculty, while developing new clinical programs at Duke Regional Hospital and Duke Health Raleigh, launching Duke's first ambulatory endoscopy center at Brier Creek and revitalizing the clinical GI program at the Durham VA Medical Center. Dr. Diehl also recruited a national leader in transplant hepatology, initiated a divisional training program in molecular epidemiology of GI diseases and implemented a tissue biobanking initiative that is fueling new inter-disciplinary research in diseases of the liver, esophagus, and intestine. As director of the T32 training program in digestive disease research, she trained and recruited 5 MD scientists/clinical investigators to the faculty.
After a decade as Chief of the Division of Gastroenterology at Duke University, Dr. Diehl assumed a new role as director of the Duke Liver Center, with a goal to growing the sizable program in basic and translational research in chronic liver disease, effective July 1, 2014. As director of the Duke Liver Center, Anna Mae will continue to seek innovations to understand the mechanisms of injury and repair in liver disorders.
Dr. Diehl remains active in basic and clinical liver research, and, has a busy clinical hepatology practice caring for patients with nonalcoholic fatty liver disease (NAFLD). Her work has led to her recognition as a thought leader in the NAFLD field. She is a member of the AASLD, AGA, ASCI, and AAP. A number of universities and professional societies have honored Dr. Diehl for her contributions to the field of hepatology and regularly invite her to present at research symposia.
Dr. Diehl is viewed internationally as an authority in the liver regeneration field and is regularly invited to present state-of-the-art lectures at major scientific meetings, to author position papers for leading biomedical research journals, and to serve on scientific review panels and advisory boards that conduct research and develop clinical practice guidelines for liver diseases.
Dr. Diehl has been voted one of the Top Doctors in the USA and selected for Who’s Who in Medicine. In the spring of 2011, the National Institutes of Alcohol Abuse and Alcoholism conferred upon her the Jack Mendelson Award, its highest honor for research that has advanced knowledge about alcohol-related diseases, and, the Board of Trustees of the Johns Hopkins University inducted her into their elite Society of Scholars. In the fall of 2012 she was presented with the AASLD Distinguished Scientific Achievement Award in honor of her sustained scientific contributions to the field of liver disease and the scientific foundations of hepatology.
Dr. Diehl’s laboratory has received uninterrupted NIH support to investigate basic mechanisms of liver regeneration for over 20 years. She was the first to demonstrate a regulatory role for the immune system in this process (via inflammatory cytokines), a discovery that shifted existing paradigms in the liver regeneration field. She identified a previously unsuspected role for Hedgehog (Hh), a fetal developmental morphogen, in adult liver repair. She was the first to demonstrate a role for Hh in hepato-carcinogenesis. She developed a clinical research program in nonalcoholic steatohepatitis (NASH) and is principal investigator for the NIH NASH Clinical Research Network based at Duke. Dr. Diehl is an author of more than 340 peer-reviewed manuscripts and reviews, and, and more than 45 book chapters.
Dr. Abdelmalek has interest in metabolic liver disease, particularly obesity-related liver disease and its association with complications of the insulin resistance syndrome. She is interested in studying the clinical, environmental, and genetic risk factors for nonalcoholic fatty liver disease, new therapeutic options for treatment, and evaluating the impact of NAFLD from a public health perspective.
Dr. Stephen A. Harrison is the Medical Director of Pinnacle Clinical Research. He earned his medical degree from the University Of Mississippi School Of Medicine. He completed his Internal Medicine residency and Gastroenterology fellowship at Brooke Army Medical Center and a 4th year advanced liver disease fellowship at Saint Louis University. He is board certified in both Internal Medicine and Gastroenterology. Dr. Harrison served as a Professor of Medicine at the Uniformed Services University of the Health Sciences and is currently a Visiting Professor of Hepatology at the Radcliffe College of Medicine, University of Oxford. He is a past Associate Editor for Hepatology and is currently an Associate Editor for Alimentary Pharmacology and Therapeutics. He is a peer-reviewer for over 20 medical journals and internationally known for studies in hepatitis C and non-alcoholic fatty liver disease with over 150 peer reviewed publications in these fields. Dr. Harrison most recently served as a Colonel in the United States Army. Retiring in 2016, he concluded 20 years of dedicated service to his country. During his army tenure, he served as the Director of Graduate Medical Education at Brooke Army Medical Center, Associate Dean for the San Antonio Uniformed Services Health Education Consortium and Gastroenterology Consultant to the Army Surgeon General.
Dr. Liddle is Professor of Medicine at Duke University Medical Center and former Chief of Division of Gastroenterology. At Duke, Dr. Liddle has held numerous leadership positions, most recently serving as Chief of the Gastroenterology Div. Dr. Liddle is an internationally recognized investigator in the physiology of the gastrointestinal tract. Dr. Liddle received his medical degree from Vanderbilt University and performed his internship and residency in Medicine at the University of California, San Francisco. He was a fellow in Gastroenterology at UCSF where he also performed his postdoctoral research training. Dr. Liddle has served on the faculties of UCSF & Duke Univ.
Dr. Sandborn is a board-certified gastroenterologist who is one of the world's top experts in the management of ulcerative colitis and Crohn’s disease. He directs the Inflammatory Bowel Disease (IBD) Center at UC San Diego Health. In addition, he is chief of the Division of Gastroenterology, vice chair of clinical operations for the Department of Medicine, and a member of the Clinical Practice Oversight (CPO) Board for UC San Diego Health. A professor in the Department of Medicine at UC San Diego School of Medicine, Dr. Sandborn conducts clinical trials in IBD and leads a team of physicians, research fellows, nurses, and study coordinators. With his physician collaborators, he evaluates and develops new diagnostic modalities and medical therapies for inflammatory bowel disease. Dr. Sandborn is internationally recognized for his contributions in the fields of biotechnology therapy, clinical pharmacology, conduct of clinical trials, diagnostic and treatment of pouchitis, epidemiology and natural history, and endoscopic and radiographic imaging techniques. His clinical trials have been instrumental to developing modern treatments for IBD. Dr. Sandborn has published nearly 600 articles in prestigious journals, including the New England Journal of Medicine, The Lancet, JAMA, the Annals of Internal Medicine, and Gastroenterology. Prior to joining UC San Diego Health, Dr. Sandborn worked in the Division of Gastroenterology and Hepatology at the Mayo Clinic in Rochester, Minn. Dr. Sandborn completed his fellowship at Mayo Clinic. He did his residency and earned his medical degree at Loma Linda University School of Medicine. He is board-certified in gastroenterology.
Dr. Feagan is a specialist in Internal Medicine, with training in clinical epidemiology and gastroenterology. His research interests focus on the design and implementation of randomized controlled trials of therapy for inflammatory bowel disease, and he has been the principal investigator on numerous multi-centre trials evaluating new treatments for the disease. Recently, Feagan began to investigate the application of cluster randomization in the evaluation of health policies. This methodology is well-suited to the assessment of the effectiveness of treatment programs, such as a care path for disease management. Dr. Feagan is a Professor of Medicine at the Schulich School of Medicine & Dentistry, a gastroenterologist at London Health Sciences Centre and Director of Robarts Clinical Trials at Robarts Research Institute.
Dr. Habtezion is an Associate Professor in the Division of Gastroenterology & Hepatology, and Immunology Program at Stanford University. Her lab is supported by the NIH and foundation grants focuses on mechanisms and immune responses in pancreatitis and inflammatory bowel disease. She is a member of NIH study section and Stanford Inflammatory Bowel Disease Program. She received B.Sc. in Chemistry from the University of Alberta, M.Sc. in Nutritional Biochemistry from the University of Guelph, and M.D. from McMaster University in Canada. She completed her Internal Medicine training at the University of Western Ontario, and her Gastroenterology & Hepatology fellowship at the University of Toronto. Following completion of her clinical training.
Dr. Lipkin is a board certified Medical Geneticist with a focus on genetic testing for gastrointestinal diseases, including the Lynch Syndrome, Familial Adenomatous Polyposis, Hemochromatosis and Hereditary Pancreatic Cancer among others. He is an authority on cancer genetic syndromes, with a particular emphasis on hereditary Gastrointestinal cancer syndromes. He is the author of MAPP-MMR, a bioinformatics program that is used to interpret whether Lynch syndrome missense variants are deleterious mutations or benign polymorphisms. He practices at Weill Medical College of Cornell University and New York-Presbyterian Hospital. He trained in Internal Medicine at Duke University and Medical Genetics at the National Human Genome Research Institute.